$SNOA
Sonoma Pharmaceuticals, Inc. Stock $snoa

$snoa Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-K Financial Statement

#000168316823004323 Filed on June 21, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2023
Revenue	$3.427M	$3.014M	$13.27M
YoY Change	-13.96%	31.16%	5.1%
Cost Of Revenue	$2.223M	$2.138M	$8.795M
YoY Change	-12.38%	-3.78%	4.49%
Gross Profit	$1.204M	$876.0K	$4.477M
YoY Change	-16.74%	1052.63%	6.32%
Gross Profit Margin	35.13%	29.06%	33.73%
Selling, General & Admin	$2.119M	$1.810M	$8.840M
YoY Change	-7.67%	-42.58%	-9.38%
% of Gross Profit	176.0%	206.62%	197.45%
Research & Development	$325.0K	$201.0K	$207.0K
YoY Change	5316.67%	4925.0%	65.6%
% of Gross Profit	26.99%	22.95%	4.62%
Depreciation & Amortization	$45.00K	$34.00K	$125.0K
YoY Change	45.16%	-30.61%	-32.8%
% of Gross Profit	3.74%	3.88%	2.79%
Operating Expenses	$2.444M	$2.011M	$9.047M
YoY Change	6.21%	-36.28%	-8.43%
Operating Profit	-$1.240M	-$1.135M	-$4.570M
YoY Change	45.03%	-63.15%	-19.39%
Interest Expense		$12.00K	$16.00K
YoY Change		-233.33%	-260.0%
% of Operating Profit
Other Income/Expense, Net	-$211.0K	-$304.0K	-$631.0K
YoY Change	214.93%	-67.52%	60.15%
Pretax Income	-$1.451M	-$1.439M	-$5.184M
YoY Change	57.38%	-56.15%	-4.32%
Income Tax	-$33.00K	-$131.0K	-$33.00K
% Of Pretax Income
Net Earnings	-$1.418M	-$1.308M	-$5.151M
YoY Change	59.86%	-55.57%	1.28%
Net Earnings / Revenue	-41.38%	-43.4%	-38.81%
Basic Earnings Per Share	-$0.29		-$1.52
Diluted Earnings Per Share	-$0.29	-$0.31	-$1.52
COMMON SHARES
Basic Shares Outstanding	4.942M shares	4.649M shares	3.394K shares
Diluted Shares Outstanding	4.936K shares		3.394K shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.544M	$3.820M	$3.820M
YoY Change	-36.56%	-48.35%	-48.35%
Cash & Equivalents	$3.544M	$3.820M	$3.820M
Short-Term Investments
Other Short-Term Assets	$4.874M	$4.548M	$703.0K
YoY Change	21.58%	14.73%	-55.87%
Inventory	$2.730M	$2.858M	$2.858M
Prepaid Expenses
Receivables	$2.439M	$2.572M	$2.572M
Other Receivables	$0.00	$0.00	$3.845M
Total Short-Term Assets	$13.59M	$13.80M	$13.80M
YoY Change	-8.3%	-16.02%	-16.02%
LONG-TERM ASSETS
Property, Plant & Equipment	$485.0K	$488.0K	$906.0K
YoY Change	56.96%	52.5%	3.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$77.00K	$73.00K	$1.527M
YoY Change	-31.25%	-5.19%	-0.59%
Total Long-Term Assets	$2.306M	$2.433M	$2.433M
YoY Change	-1.5%	0.75%	0.75%
TOTAL ASSETS
Total Short-Term Assets	$13.59M	$13.80M	$13.80M
Total Long-Term Assets	$2.306M	$2.433M	$2.433M
Total Assets	$15.89M	$16.23M	$16.23M
YoY Change	-7.37%	-13.87%	-13.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.090M	$841.0K	$841.0K
YoY Change	-47.01%	-48.75%	-48.75%
Accrued Expenses	$2.488M	$2.285M	$1.719M
YoY Change	13.87%	9.17%	31.32%
Deferred Revenue
YoY Change
Short-Term Debt	$301.0K	$431.0K	$431.0K
YoY Change	-34.42%	-37.35%	-37.35%
Long-Term Debt Due		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Short-Term Liabilities	$4.041M	$3.717M	$3.717M
YoY Change	-16.75%	-36.12%	-36.12%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%
Other Long-Term Liabilities	$4.610M	$4.537M	$4.537M
YoY Change	6.47%	4.8%	4.8%
Total Long-Term Liabilities	$4.610M	$4.537M	$4.537M
YoY Change	30633.33%		4.8%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.041M	$3.717M	$3.717M
Total Long-Term Liabilities	$4.610M	$4.537M	$4.537M
Total Liabilities	$8.651M	$8.254M	$8.254M
YoY Change	-5.96%	-18.66%	-18.66%
SHAREHOLDERS EQUITY
Retained Earnings	-$190.9M	-$189.5M
YoY Change	3.07%	2.79%
Common Stock	$201.1M	$200.9M
YoY Change	1.77%	1.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$7.242M	$7.977M	$7.977M
YoY Change
Total Liabilities & Shareholders Equity	$15.89M	$16.23M	$16.23M
YoY Change	-7.37%	-13.87%	-13.87%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2023
OPERATING ACTIVITIES
Net Income	-$1.418M	-$1.308M	-$5.151M
YoY Change	59.86%	-55.57%	1.28%
Depreciation, Depletion And Amortization	$45.00K	$34.00K	$125.0K
YoY Change	45.16%	-30.61%	-32.8%
Cash From Operating Activities	-$215.0K	-$2.441M	-$6.152M
YoY Change	-85.98%	74.98%	44.82%
INVESTING ACTIVITIES
Capital Expenditures	$17.00K	$190.0K	$269.0K
YoY Change	-26.09%	-406.45%	-296.35%
Acquisitions
YoY Change
Other Investing Activities		$108.0K	$11.00K
YoY Change		10700.0%	-71.05%
Cash From Investing Activities	-$17.00K	-$82.00K	-$258.0K
YoY Change	-26.09%	34.43%	160.61%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$2.868M
YoY Change			-63.09%
Debt Paid & Issued, Net			$774.0K
YoY Change			2480.0%
Cash From Financing Activities	-$135.0K	3.372M	$2.489M
YoY Change	-65.12%	1418.92%	-66.35%
NET CHANGE
Cash From Operating Activities	-$215.0K	-2.441M	-$6.152M
Cash From Investing Activities	-$17.00K	-82.00K	-$258.0K
Cash From Financing Activities	-$135.0K	3.372M	$2.489M
Net Change In Cash	-$276.0K	849.0K	-$3.576M
YoY Change	-84.75%	-168.8%	-217.28%
FREE CASH FLOW
Cash From Operating Activities	-$215.0K	-$2.441M	-$6.152M
Capital Expenditures	$17.00K	$190.0K	$269.0K
Free Cash Flow	-$232.0K	-$2.631M	-$6.421M
YoY Change	-85.09%	97.37%	56.19%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001367083
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-33216
CY2023	dei	Entity Registrant Name EntityRegistrantName	SONOMA PHARMACEUTICALS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	68-0423298
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	5445 Conestoga Court
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 150
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Boulder
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CO
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	80301
CY2023	dei	City Area Code CityAreaCode	(800)
CY2023	dei	Local Phone Number LocalPhoneNumber	759-9305
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
CY2023	dei	Trading Symbol TradingSymbol	SNOA
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Public Float EntityPublicFloat	6580267000	usd
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	4941596	shares
CY2023	dei	Auditor Firm AuditorFirmId	215
CY2023	dei	Auditor Name AuditorName	Frazier & Deeter, LLC
CY2023	dei	Auditor Location AuditorLocation	Atlanta, Georgia
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3820000	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7396000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2572000	usd
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2407000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	2858000	usd
CY2022Q1	us-gaap	Inventory Net InventoryNet	2663000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4308000	usd
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3746000	usd
CY2023Q1	SNOA	Deferred Consideration Net Current DeferredConsiderationNetCurrent	240000	usd
CY2022Q1	SNOA	Deferred Consideration Net Current DeferredConsiderationNetCurrent	218000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	13798000	usd
CY2022Q1	us-gaap	Assets Current AssetsCurrent	16430000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	488000	usd
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	320000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	418000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	559000	usd
CY2023Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	949000	usd
CY2022Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	829000	usd
CY2023Q1	SNOA	Deferred Consideration Net Noncurrent DeferredConsiderationNetNoncurrent	505000	usd
CY2022Q1	SNOA	Deferred Consideration Net Noncurrent DeferredConsiderationNetNoncurrent	630000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	73000	usd
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	77000	usd
CY2023Q1	us-gaap	Assets Assets	16231000	usd
CY2022Q1	us-gaap	Assets Assets	18845000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	841000	usd
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1641000	usd
CY2023Q1	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	2029000	usd
CY2022Q1	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	1843000	usd
CY2023Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	100000	usd
CY2022Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1223000	usd
CY2023Q1	SNOA	Contract With Customer Liability Current Invekra ContractWithCustomerLiabilityCurrentInvekra	60000	usd
CY2022Q1	SNOA	Contract With Customer Liability Current Invekra ContractWithCustomerLiabilityCurrentInvekra	54000	usd
CY2023Q1	us-gaap	Notes Payable Current NotesPayableCurrent	0	usd
CY2022Q1	us-gaap	Notes Payable Current NotesPayableCurrent	120000	usd
CY2023Q1	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	431000	usd
CY2022Q1	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	688000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	256000	usd
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	250000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3717000	usd
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	5819000	usd
CY2023Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	140000	usd
CY2022Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	182000	usd
CY2023Q1	SNOA	Withholding Tax Payable WithholdingTaxPayable	4235000	usd
CY2022Q1	SNOA	Withholding Tax Payable WithholdingTaxPayable	3838000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	162000	usd
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	309000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	8254000	usd
CY2022Q1	us-gaap	Liabilities Liabilities	10148000	usd
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	24000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	24000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4933550	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4933550	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3100937	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3100937	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	5000	usd
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	200904000	usd
CY2022Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	197370000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-189514000	usd
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-184363000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3418000	usd
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4312000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	7977000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	8697000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16231000	usd
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18845000	usd
CY2023	us-gaap	Revenues Revenues	13272000	usd
CY2022	us-gaap	Revenues Revenues	12628000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8795000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8635000	usd
CY2023	us-gaap	Gross Profit GrossProfit	4477000	usd
CY2022	us-gaap	Gross Profit GrossProfit	3993000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	207000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	125000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8840000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9755000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	9047000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	9880000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-4570000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-5887000	usd
CY2023	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	16000	usd
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-10000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	723000	usd
CY2023	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-631000	usd
CY2022	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-394000	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	1000	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	150000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5184000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5418000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-33000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-332000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5151000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-5086000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.52
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.52
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.92
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.92
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3394	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3394	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2653	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2653	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5151000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-5086000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	894000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	267000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-4257000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-4819000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	8697000	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	2868000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	649000	usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	20000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	894000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5151000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	7977000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	5363000	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	7554000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	193000	usd
CY2022	SNOA	Shares Issued In Connection With Exercise Of Common Stock Warrants Amount SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount	24000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	372000	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	10000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	267000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-5086000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	8697000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5151000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-5086000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	125000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	186000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-125000	usd
CY2023	SNOA	Recovery Of Discounts Rebates Distributor Fees And Returns RecoveryOfDiscountsRebatesDistributorFeesAndReturns	-66000	usd
CY2022	SNOA	Recovery Of Discounts Rebates Distributor Fees And Returns RecoveryOfDiscountsRebatesDistributorFeesAndReturns	-1407000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	669000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	382000	usd
CY2023	SNOA	Forgiveness Of Ppp Loan ForgivenessOfPppLoan	-0	usd
CY2022	SNOA	Forgiveness Of Ppp Loan ForgivenessOfPppLoan	723000	usd
CY2023	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	37000	usd
CY2022	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	829000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-173000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-223000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	1000	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-0	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-62000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1971000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-0	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	100000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	306000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	460000	usd
CY2023	SNOA	Increase Decrease In Deferred Consideration Net Of Discount IncreaseDecreaseInDeferredConsiderationNetOfDiscount	190000	usd
CY2022	SNOA	Increase Decrease In Deferred Consideration Net Of Discount IncreaseDecreaseInDeferredConsiderationNetOfDiscount	160000	usd
CY2023	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-864000	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-157000	usd
CY2023	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	127000	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	679000	usd
CY2023	SNOA	Increase Decrease In Withholding Tax Payable IncreaseDecreaseInWithholdingTaxPayable	396000	usd
CY2022	SNOA	Increase Decrease In Withholding Tax Payable IncreaseDecreaseInWithholdingTaxPayable	360000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-173000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-222000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1296000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	900000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6152000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4248000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	269000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	137000	usd
CY2023	SNOA	Increase Decrease In Deposit1 IncreaseDecreaseInDeposit1	-11000	usd
CY2022	SNOA	Increase Decrease In Deposit1 IncreaseDecreaseInDeposit1	-38000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-258000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-99000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2868000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	7554000	usd
CY2023	SNOA	Payments On Ppp Loan PaymentsOnPppLoan	120000	usd
CY2022	SNOA	Payments On Ppp Loan PaymentsOnPppLoan	467000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	216000	usd
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	774000	usd
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	30000	usd
CY2023	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	515000	usd
CY2022	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	123000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2489000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7396000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	345000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	127000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3576000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3176000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7396000	usd
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4220000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3820000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7396000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	17000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	24000	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	767000	usd
CY2023	SNOA	Insurance Premiums Financed InsurancePremiumsFinanced	515000	usd
CY2022	SNOA	Insurance Premiums Financed InsurancePremiumsFinanced	748000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5151000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-5086000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-189514000	usd
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-184363000	usd
CY2023Q1	SNOA	Working Capital WorkingCapital	10081000	usd
CY2022Q1	SNOA	Working Capital WorkingCapital	10611000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6152000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4248000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	894000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	267000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_842_eus-gaap--UseOfEstimates_zyBK9pExW3Bi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86B_zpVdVNJ2thk6">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include reserves and write-downs related to receivables and inventories, the recoverability of long-lived assets, the valuation allowance relating to the Company’s deferred tax assets, valuation of options, and the estimated amortization periods of upfront product licensing fees received from customers. Periodically, the Company evaluates and adjusts estimates accordingly.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zXrW0XmNyfw2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_866_zflKeAACQ055">Concentration of Credit Risk and Major Customers</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash, cash equivalents and accounts receivable. Cash and cash equivalents are maintained in financial institutions in the United States, Mexico and the Netherlands. The Company is exposed to credit risk in the event of default by these financial institutions for amounts in excess of the Federal Deposit Insurance Corporation insured limits. Cash and cash equivalents held in foreign banks are intentionally kept at minimal levels, and therefore have minimal credit risk associated with them. We currently have $2.5 million of deposits above federally insured limits.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company grants credit to its business customers, which are primarily located in Mexico, Europe and the United States. Collateral is generally not required for trade receivables. The Company maintains allowances for potential credit losses. At March 31, 2023, customer A represented <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zL0dlcJHU6af" title="Significant customer concentration">22</span>% of our net accounts receivable balance and customer D represented <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zs1vKmh6EHP9" title="Significant customer concentration">21</span>% of our net accounts receivable balance. At March 31, 2022, customer B represented <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z6aa496zSsB1" title="Significant customer concentration">20</span>% of our net accounts receivable balance, customer D represented <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbJ5PnLWHdP8" title="Significant customer concentration">15</span>% of our net accounts receivable balance, and customer E represented <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zF3HW4qhQNKc" title="Significant customer concentration">14</span>% of our net accounts receivable balance. For the year ended March 31, 2023, customer A represented <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zs52YZ0ezIm3" title="Significant customer concentration">16</span>%, customer B represented <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z421KB9HaSEa" title="Significant customer concentration">18</span>% and customer C represented <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zfPok6TByUWa" title="Significant customer concentration">11</span>% of net revenues. For the year ended March 31, 2022, customer C represented <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z5JTjoCqGj68" title="Significant customer concentration">10</span>%, customer B represented <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWRg1vNa7xn3" title="Significant customer concentration">17</span>%, and customer A represented <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zDPlIfAMmwal" title="Significant customer concentration">21</span>% of net revenues.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p>
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2023Q1	SNOA	Allowance For Sales Discounts Rebates Distributor Fees And Returns AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns	16000	usd
CY2022Q1	SNOA	Allowance For Sales Discounts Rebates Distributor Fees And Returns AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns	81000	usd
CY2023	us-gaap	Foreign Currency Transaction Loss Before Tax ForeignCurrencyTransactionLossBeforeTax	692000	usd
CY2022	us-gaap	Foreign Currency Transaction Loss Before Tax ForeignCurrencyTransactionLossBeforeTax	579000	usd
CY2023Q1	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	122000	usd
CY2022Q1	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	108000	usd
CY2023Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	554000	usd
CY2022Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	503000	usd
CY2023Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	236000	usd
CY2022Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	218000	usd
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet	0	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet	0	usd
CY2022	SNOA	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-1.92
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2502000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	207000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	125000	usd
CY2023	us-gaap	Marketing Expense MarketingExpense	156000	usd
CY2022	us-gaap	Marketing Expense MarketingExpense	86000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3418000	usd
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4312000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5151000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-5086000	usd
CY2023	SNOA	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	3394	shares
CY2022	SNOA	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	2653	shares
CY2023	SNOA	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-1.52
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	715	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	621	shares
CY2022Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1281000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	202000	usd
CY2022Q1	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	139000	usd
CY2023Q1	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	2588000	usd
CY2022Q1	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	2488000	usd
CY2023Q1	SNOA	Discounts Rebates Distributor Fees And Returns DiscountsRebatesDistributorFeesAndReturns	16000	usd
CY2022Q1	SNOA	Discounts Rebates Distributor Fees And Returns DiscountsRebatesDistributorFeesAndReturns	81000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2572000	usd
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2407000	usd
CY2023Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1764000	usd
CY2022Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1626000	usd
CY2023Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1094000	usd
CY2022Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1037000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	2858000	usd
CY2022Q1	us-gaap	Inventory Net InventoryNet	2663000	usd
CY2023Q1	us-gaap	Prepaid Insurance PrepaidInsurance	438000	usd
CY2022Q1	us-gaap	Prepaid Insurance PrepaidInsurance	755000	usd
CY2023Q1	us-gaap	Prepaid Taxes PrepaidTaxes	3845000	usd
CY2022Q1	us-gaap	Prepaid Taxes PrepaidTaxes	2371000	usd
CY2023Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	25000	usd
CY2022Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	620000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4308000	usd
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3746000	usd
CY2023Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1624000	usd
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2031000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2014000	usd
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1711000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	488000	usd
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	320000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	125000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	186000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1463000	usd
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1059000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	566000	usd
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	784000	usd
CY2023Q1	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	2029000	usd
CY2022Q1	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	1843000	usd
CY2023	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	723000	usd
CY2023Q1	us-gaap	Loans Payable LoansPayable	0	usd
CY2022Q1	us-gaap	Loans Payable LoansPayable	120000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	418000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	559000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	256000	usd
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	250000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	162000	usd
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	309000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	385000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	367000	usd
CY2023	us-gaap	Operating Lease Payments Use OperatingLeasePaymentsUse	173000	usd
CY2022	us-gaap	Operating Lease Payments Use OperatingLeasePaymentsUse	222000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P19M12D
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P27M9D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.06	pure
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.06	pure
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	296000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	154000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	15000	usd
CY2023Q1	SNOA	Lessee Operating Lease Liability Payments Due After Year Three LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree	0	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	465000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	47000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	418000	usd
CY2023	us-gaap	Salaries And Wages SalariesAndWages	575000	usd
CY2023	us-gaap	Severance Costs1 SeveranceCosts1	862500	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	24000000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	836593	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.09
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.60
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0392	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0160	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.1088	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.2327	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.92
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.03
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	669000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	382000	usd
CY2023Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	20000	usd
CY2023	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	102000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	565027	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	0	shares
CY2023Q1	SNOA	Share Based Compensation Arrangement By Share Based Payment Awards Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber	565027	shares
CY2023	us-gaap	Profit Loss ProfitLoss	-5182000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-5399000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	8000	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	469000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	477000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-35000	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-809000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-33000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-332000	usd
CY2022Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	30613000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1127000	usd
CY2022Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1169000	usd
CY2023Q1	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	16000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.008	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.057	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.065	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.037	pure
CY2023	SNOA	Foreign Tax Trueup ForeignTaxTrueup	0	pure
CY2022	SNOA	Foreign Tax Trueup ForeignTaxTrueup	0	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.075	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.030	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.161	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.123	pure
CY2023	SNOA	Trueups Of State Deferred Assets TrueupsOfStateDeferredAssets	0.013	pure
CY2022	SNOA	Trueups Of State Deferred Assets TrueupsOfStateDeferredAssets	-0.256	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.060	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.105	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.054	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.167	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.006	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.062	pure
CY2023Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	28558000	usd
CY2022Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	28224000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1800000	usd
CY2022Q1	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1850000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	739000	usd
CY2022Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	309000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	795000	usd
CY2022Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	1336000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	20000	usd
CY2022Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	0	usd
CY2023Q1	SNOA	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	24000	usd
CY2022Q1	SNOA	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	63000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	31936000	usd
CY2022Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	31782000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	30809000	usd
CY2022Q1	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	17000	usd
CY2023Q1	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	138000	usd
CY2022Q1	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	260000	usd
CY2023Q1	SNOA	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	24000	usd
CY2022Q1	SNOA	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	63000	usd
CY2023Q1	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	178000	usd
CY2022Q1	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	339000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	949000	usd
CY2022Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	829000	usd
CY2023	us-gaap	Pension And Other Postretirement Benefit Contributions PensionAndOtherPostretirementBenefitContributions	101000	usd
CY2022	us-gaap	Pension And Other Postretirement Benefit Contributions PensionAndOtherPostretirementBenefitContributions	51000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13272000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12628000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13272000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12628000	usd

Files In Submission

Name	View Source	Status
0001683168-23-004323-index-headers.html	Edgar Link	pending
0001683168-23-004323-index.html	Edgar Link	pending
0001683168-23-004323.txt	Edgar Link	pending
0001683168-23-004323-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
image_008.jpg	Edgar Link	pending
image_009.jpg	Edgar Link	pending
image_010.jpg	Edgar Link	pending
image_011.jpg	Edgar Link	pending
image_012.jpg	Edgar Link	pending
image_013.jpg	Edgar Link	pending
image_014.jpg	Edgar Link	pending
image_015.jpg	Edgar Link	pending
image_016.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
snoa-20230331.xsd	Edgar Link	pending
sonoma_ex1038.htm	Edgar Link	pending
sonoma_ex1039.htm	Edgar Link	pending
sonoma_ex3101.htm	Edgar Link	pending
sonoma_ex3102.htm	Edgar Link	pending
sonoma_ex3201.htm	Edgar Link	pending
sonoma_i10k-033123.htm	Edgar Link	pending
snoa-20230331_cal.xml	Edgar Link	unprocessable
snoa-20230331_lab.xml	Edgar Link	unprocessable
snoa-20230331_def.xml	Edgar Link	unprocessable
snoa-20230331_pre.xml	Edgar Link	unprocessable
sonoma_i10k-033123_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SNOA
Sonoma Pharmaceuticals, Inc. Stock $snoa

2023 Q2 Form 10-K Financial Statement

#000168316823004323 Filed on June 21, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SNOA Sonoma Pharmaceuticals, Inc. Stock $snoa

2023 Q2 Form 10-K Financial Statement

#000168316823004323 Filed on June 21, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SNOA
Sonoma Pharmaceuticals, Inc. Stock $snoa